Found 400 results in Expert Content

Summary: Catalent encourages employees to make a difference in their local communities. Hear how Mike and his family made a difference for children with special needs at.​...

Summary: ALK-Abelló A/S is a Denmark-based pharmaceutical company that specializes in the development of immunotherapy products for the treatment of respiratory allergies. ALK partnered with Catalent for...

Summary: Watch this webinar to get insight from manufacturing experts on the benefits of end-to-end solutions and how flexible manufacturing strategies can accommodate the changing landscape of the pharmaceutical industry.

Summary: Catalent can formulate and fill your product into vial, syringe, or cartridge injectable formats that are ready-to-use (RTU) for the patient or healthcare professional...

Summary: The USP general chapter “Package Integrity Evaluation – Sterile Product” deeply changes the way it considers the Container Closure Integrity Testing (CCIT) within the pharmaceutical...

Summary: MGB Biopharma, a biotech company based in Scotland, U.K. was developing a new class of anti-infective medicine based on Minor Groove Binder compounds. Learn how Catalent provided integrated formulation...

Summary: Planning for a clinical supply project? Having a well-thought out packaging design strategy is crucial. Download the eBook today to get expert insights on the best packaging strategies to solve stability and blinding concerns...

Summary: A Catalent customer wanted to run a clinical trial in Israel and was arranging to ship their clinical trial product from a non-Catalent facility in Europe to a Catalent-managed and audited depot in Israel. With the protocol based...

Summary: Advanced analytical techniques can provide timely insights into a product’s stability, performance, and composition. Download this webinar to get expert insights on the applications of analytical techniques to help answer various questions...

Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. Nearly 40% of the new chemical entities (NCEs) screened by pharmaceutical...